HER2-positive Breast Cancer
Conditions
Brief summary
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
Interventions
DIAGNOSTIC_TESTGeoMx data analysis with clinical outcome
1. List of HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples 2. Prepare tissue for digital spatial proteomics * FFPE/H&E slide * Region of Interest(ROI) check * Make a Tissue microarray * Prepare special slide for GeoMx 3. GeoMx data analysis with clinical outcome
Sponsors
Samsung Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
Yes
Inclusion criteria
* HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples
Exclusion criteria
* TNBC breast cancer * Hormone receptor positive breast cancer * Non-available FFPE samples * Treated except T-Dxd
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Spatial transcriptomic analysis | Before chemotherapy, curative surgery | Protein expression and relationship protein-protein in HER2 positive breast cancer tumor cells and tumor microenvironment. |
Countries
South Korea
Contacts
Primary ContactJi-Yeon Kim
Backup ContactMIRYOUNG HONG
Outcome results
None listed